Apellis Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2016 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Apellis Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2016 to Q4 2023.
  • Apellis Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $753M, a 18.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $753M +$117M +18.4% Dec 31, 2023 10-K/A 2024-02-29
Q4 2022 $637M +$97.7M +18.1% Dec 31, 2022 10-K/A 2024-02-29
Q4 2021 $539M +$142M +35.7% Dec 31, 2021 10-K 2023-02-21
Q4 2020 $397M +$240M +153% Dec 31, 2020 10-K 2022-02-28
Q4 2019 $157M +$77.6M +97.7% Dec 31, 2019 10-K 2021-02-25
Q4 2018 $79.4M +$38.2M +92.6% Dec 31, 2018 10-K 2020-02-27
Q4 2017 $41.2M +$11.2M +37.2% Dec 31, 2017 10-K 2019-02-26
Q4 2016 $30M Dec 31, 2016 10-K 2018-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.